63,741 Shares in Sionna Therapeutics, Inc. $SION Acquired by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. acquired a new position in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 63,741 shares of the company’s stock, valued at approximately $667,000. Goldman Sachs Group Inc. owned approximately 0.14% of Sionna Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Siren L.L.C. purchased a new position in Sionna Therapeutics during the first quarter worth approximately $3,400,000. Zimmer Partners LP purchased a new stake in Sionna Therapeutics in the first quarter valued at $2,484,000. Alyeska Investment Group L.P. purchased a new stake in Sionna Therapeutics in the first quarter valued at $1,948,000. Charles Schwab Investment Management Inc. purchased a new stake in Sionna Therapeutics in the first quarter valued at $676,000. Finally, Jennison Associates LLC purchased a new stake in Sionna Therapeutics in the first quarter valued at $8,995,000.

Insider Buying and Selling

In related news, major shareholder Tpg Gp A, Llc bought 60,000 shares of the stock in a transaction on Friday, June 27th. The shares were purchased at an average price of $15.84 per share, for a total transaction of $950,400.00. Following the acquisition, the insider owned 6,744,962 shares in the company, valued at $106,840,198.08. This represents a 0.90% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Michael Cloonan sold 7,426 shares of the stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $25.01, for a total value of $185,724.26. Following the transaction, the chief executive officer directly owned 547,343 shares in the company, valued at approximately $13,689,048.43. This represents a 1.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 58,000 shares of company stock worth $1,466,671 in the last quarter. Company insiders own 3.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Jones Trading assumed coverage on Sionna Therapeutics in a research report on Monday, September 8th. They issued a “buy” rating and a $46.00 target price on the stock. Raymond James Financial assumed coverage on Sionna Therapeutics in a research report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $45.00 target price on the stock. Royal Bank Of Canada assumed coverage on Sionna Therapeutics in a research report on Wednesday, September 3rd. They issued a “sector perform” rating and a $22.00 target price on the stock. Finally, Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $38.00.

Sionna Therapeutics Stock Up 1.3%

Shares of NASDAQ SION opened at $27.08 on Thursday. The business has a 50-day moving average of $21.59 and a two-hundred day moving average of $16.65. Sionna Therapeutics, Inc. has a 1 year low of $7.26 and a 1 year high of $27.49.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.27.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.